Metabolic switch from oxidative phosphorylation to aerobic glycolysis, which is also called the Warburg effect, is a hallmark of osteosarcoma (OS) and leads to the enhancement of cell chemoresistance, growth, metastasis, and invasion. Emerging evidence indicates that long non-coding RNA (lncRNA) plays a crucial role in the Warburg effect of cancer cells. Here, we report that lncRNA KCNQ1OT1 was upregulated in OS. Meanwhile, functional experiments demonstrated that the KCNQ1OT1 facilitated proliferation and suppressed apoptosis of OS cells. In addition, KCNQ1OT1 contributed to the Warburg effect by stimulating aldolase A (ALDOA) expression. Furthermore, using bioinformatics analysis, luciferase reporter, RNA immunoprecipitation, and RNA pull-down assay, we identified that KCNQ1OT1 functions as a competing endogenous RNA (ceRNA) by sponging miR-34c-5p, which inhibited ALDOA expression by directly targeting its 3ʹUTR. Taken together, these data identified a key role of KCNQ1OT1 in glucose metabolism reprogramming of OS. Targeting the KCNQ1OT1/miR-34c-5p/ALDOA axis may be a potential therapeutic target in OS treatment.
Osteosarcoma (OS) is one of the most aggressive and common primary malignant bone tumors, and it occurs most frequently in children and adolescents1. Due to advances in various treatment strategies such as surgery, chemotherapy, and radiotherapy, the five-year survival rate of OS in non-metastatic OS patients has reached 60%2. However, the overall survival rate has not markedly increased over the last decade because the molecular mechanisms underlying the pathogenesis and progression of OS are poorly understood3. Thus, it is of great importance to explore the molecular mechanisms related with the OS progression and pathogenesis and to identify more effective therapeutic targets.
Aerobic glycolysis is a general feature of energy metabolism in cancer cells, and it is also termed the Warburg effect4,5,6. Although aerobic glycolysis is less efficient in the generation of adenosine triphosphate (ATP), it increases proliferation, inhibits apoptosis, and generates signaling metabolites to enhance cancer cell survival under molecularly stressful conditions7,8. Fructose-bisphosphate aldolase A (ALDOA), a glycolytic enzyme, plays an important role in glycolysis and gluconeogenesis9. Notably, ALDOA is highly expressed and acts as an oncogene in many types of cancers including lung squamous cell carcinomas, colorectal cancer, hepatocellular carcinomas, and oral squamous cell carcinomas10,11,12,13. Previous studies have reported that ALDOA is upregulated in OS and is a negative survival marker of these patients14,15. However, the role of ALDOA in OS progression and its underlying molecular mechanisms remain unclear.
Long non-coding RNA (lncRNA) is a subtype of RNA longer than 200 nucleotides that lacks protein-coding functions16. The lncRNA plays a crucial role in regulating gene expression at different stages including chromatin remodeling, transcription, and post-transcriptional regulation17,18. Notably, lncRNA also functions as a competing endogenous RNA (ceRNA) that sponges microRNAs (miRNAs) that target messenger RNA (mRNA) expression19,20. Recent reports have shown that different lncRNA transcripts play important roles in initiation, progression, and development of multiple tumors as either oncogenes or tumor suppressor genes21,22,23. KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) is a type of long chromatin-interacting lncRNA that has been widely reported to be a cancer promoter in various types of tumors such as non-small cell lung carcinoma, colorectal cancer, tongue cancer, and breast cancer24,25,26,27.
In this study, we demonstrated that KCNQ1OT1 was upregulated in OS and promoted tumor growth by contributing to aerobic glycolysis. Mechanistically, KCNQ1OT1 competes with a key glycolytic coding mRNA, ALDOA, for miR-34c-5p and relieves the inhibitory effect of miR-34c-5p on ALDOA, thereby leading to increased ALDOA expression and aerobic glycolysis. Thus, the KCNQ1OT1-miR-34c-5p/ALDOA axis may provide a new therapeutic target for OS treatment.
LncRNA KCNQ1OT1 was upregulated in OS and promoted the growth of the OS cells
In order to explore the role of KCNQ1OT1 in OS progression, we first determined the expression patterns of KCNQ1OT1 via comparing the expression levels of KCNQ1OT1 in four OS cell lines (U-2OS, 143B, MG63, and Saos-2), with that of a normal human osteoblast cell line (hFOB1.19) via real-time polymerase chain reaction (qRT-PCR). As displayed in Fig. 1a, all of the OS cell lines exhibited significantly higher expression of KCNQ1OT1 than the control human osteoblast cell line, especially in the U-2OS and 143B cells. Further exploration of the biological function of KCNQ1OT1 in the progression of OS, involved two short hairpin RNA (sh-1, sh-2) against KCNQ1OT1 and the non-targeting shRNA (sh-CON) were designed and stable KCNQ1OT1 knockdown U-2OS and 143B cell lines were established. The knockdown efficiency was evaluated by qRT-PCR (Supplementary Fig. 1a). The cell counting kit-8 (CCK-8) assay (Fig. 1b, c), EdU assay (Fig. 1d), colony formation assay (Fig. 1e and Supplementary Fig. 1b), and cell cycle assay (Fig. 1f and Supplementary Fig. 1c, d) showed that knockdown of KCNQ1OT1 partly inhibited the proliferation of U-2OS and 143B cells. Next, we evaluated the effects of KCNQ1OT1 knockdown on cell apoptosis. As depicted in Fig. 1g, h, compared with the control cells, downregulation of KCNQ1OT1 significantly induced the apoptosis of the OS cells.
Furthermore, to determine whether KCNQ1OT1 promoted growth of the OS cells in vivo, we utilized xenograft experiments by subcutaneously injecting stable KCNQ1OT1-knockdown or control U-2OS cells into nude mice. We found that the stable KCNQ1OT1-knockdown group exhibited significantly decreased the xenografted tumor growth and a decreased tumor burden compared to the control group (Fig. 2a–d). Immunohistochemical staining and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay revealed declining expression of Ki67 and a rising rate of apoptosis in the xenografted tumors of KCNQ1OT1-knockdown group (Fig. 2e). To further explore the mechanism of regulation of KCNQ1OT1 on cell proliferation and apoptosis, we detected several apoptosis-related and cell cycle-related molecules by western blotting. The results showed that knockdown of KCNQ1OT1 effectively promoted the activated levels of cleaved Caspase-3, cleaved Caspase-7 and cleaved Caspase-9 and inhibit the expression of cyclin-dependent kinase 4 (CDK4) and Cyclin D1 (Supplementary Fig. 2a). These data further indicate that KCNQ1OT1 was upregulated in OS cell lines and promoted cell survival through inhibiting cell apoptosis and facilitating proliferation of OS cells both in vitro and in vivo.
KCNQ1OT1 contributed to the Warburg effect in OS
It has been widely accepted that metabolic shift from oxidative phosphorylation to aerobic glycolysis, also called the Warburg effect, contributes to the promotion of growth and apoptosis avoidance in tumors28. To assess whether KCNQ1OT1 contributes to bioenergetic changes in OS, we used a metabolic flux analyzer to measure extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) in KCNQ1OT-knockdown and control OS cells. Silencing KCNQ1OT1 significantly suppressed the ECAR in U-2OS and 143B cells (Fig. 2f, g) but enhanced OCR in these cells (Fig. 2h, i). Furthermore, knockdown of KCNQ1OT1 in OS cells also promoted the level of ATP produced by oxidative phosphorylation and decreased the formation of lactate produced by aerobic glycolysis (Fig. 2j, k). Collectively, these results showed that KCNQ1OT1 inhibited oxidative phosphorylation and facilitated aerobic glycolysis in OS.
KCNQ1OT1 promoted OS growth via ALDOA-mediated glycolysis
To investigate how KCNQ1OT1 regulated glucose metabolism in OS, a panel of genes involved in the glycolysis pathway and tricarboxylic acid (or Krebs) cycle were measured by qRT-PCR in U-2OS and 143B cells with altered KCNQ1OT1 expression. qRT–PCR analysis showed that knockdown of KCNQ1OT1 significantly suppressed mRNA expression of ALDOA, a key glycolytic gene, in U-2OS and 143B cells (Supplementary Fig. 3a, b). We also compared the expression level of ALDOA in OS cell lines (U-2OS, 143B, and MG63), with that in hFOB1.19. As shown in Supplementary Fig. 3c, all these OS cell lines showed significantly higher expression of ALDOA than the hFOB1.19. Next, we determined whether KCNQ1OT1 participates in OS growth by regulating ALDOA-mediated glycolysis. First, we overexpressed ALDOA in wild-type (WT) and KCNQ1OT1 knockdown OS cell lines and confirmed overexpression efficiency by western blot (Fig. 3a). As shown in Fig. 3b–d and Supplementary Fig. 3d, overexpression of ALDOA partly reversed the inhibited effects of KCNQ1OT1 knockdown on the growth-promoting properties of OS cells. The results of in vivo xenograft experiments showed that anti-tumorigenic effects on KCNQ1OT1-knockdown group were partly reversed by ALDOA overexpression (Fig. 3e, f). In addition, ALDOA overexpression also partly restored the Warburg effect in U-2OS and 143B cells (Fig. 3g–j). Kaplan–Meier analysis from the R2 database was used to determine the prognostic significance of ALDOA in OS patients. As shown in Supplementary Fig. 3e, high ALDOA expression contributed to a lower overall survival rate in patients with OS. Collectively, these results validated that KCNQ1OT1 influences ALDOA-mediated glycolysis and then promotes OS growth.
miR-34c-5p directly targeted ALDOA in OS cells
It has been reported that some lncRNA sponges microRNAs to regulate the target gene expression. We found five potential microRNAs that target ALDOA and are regulated by KCNQ1OT1 by overlap in three commonly used prediction algorithms TargetScan, miRDB and Starbase (Fig. 4a). We therefore overexpressed these above five miRNAs in U-2OS and 143B cells by transfecting miRNA mimics. Overexpression efficiency was confirmed by qRT-PCR (Supplementary Fig. 4a, b). Overexpression of miR-34c-5p significantly suppressed mRNA and protein expression of ALDOA in U-2OS and 143B cells (Fig. 4b–d). Furthermore, hFOB1.19 showed significantly higher expression of miR-34c-5p than the OS cell lines (Supplementary Fig. 4c). The potential target site of miR‑34c-5p on ALDOA is shown in Fig. 4e. Dual luciferase reporter assays were used to further confirm that miR-34c-5p directly targets ALDOA. These results showed that the miR-34c-5p mimic led to a significant reduction in the luciferase activity of the WT ALDOA 3′UTR (ALDOA-WT) reporter, but not in the Mut 3′UTR of ALDOA reporter U-2OS and 143B cells (Fig. 4f–g). Furthermore, RNA immunoprecipitation (RIP) assay revealed a higher enrichment level of ALDOA in the Argonaute 2 (Ago2) group after overexpression of miR-34c-5p (Fig. 4h–i). Taken together, these data showed that miR-34c-5p inhibited ALDOA expression by directly targeting its 3ʹUTR.
KCNQ1OT1 functioned as a ceRNA by sponging miR-34c-5p
To further investigate whether KCNQ1OT1 acted as a sponge to miR-34c-5p in OS cells, we measured the miR-34c-5p expression in KCNQ1OT1-knockdown and control U-2OS and 143B cells. Silencing of KCNQ1OT1 significantly increased the expression level of miR-34c-5p in OS cells (Fig. 5a). Furthermore, bioinformatics analysis revealed that ALDOA contains a putative binding site of miR-34c-5p (Fig. 5b). Meanwhile, we constructed plasmids containing either WT or mutated type (MUT) miR-34c-5p binding site of the KCNQ1OT1 transcript combined with an MS2 binding site and co-transfected these into U-2OS or 143B cell lines with a construct containing MS2-binding protein (MS2bp) and GFP. An MS2-based RIP assay was performed, and as shown in Fig. 5c, miR-34c-5p was significantly enriched in RNAs retrieved from the WT MS2bs-KCNQ1OT1 group compared with the MUT MS2bs-KCNQ1OT1 group. RNA pull-down assay further revealed that miR-34c-5p bound biotin-labeled WT KCNQ1OT1 but not MUT KCNQ1OT1 (Fig. 5d). Subsequently, a luciferase reporter construct containing KCNQ1OT1 (WT or MUT miR-34c-5p binding site) was generated and co-transfected into U-2OS cells and 143B cells with miR-34c-5p mimics. The results of luciferase assay showed that upregulation of miR-34c-5p enhanced the luciferase activity of WT KCNQ1OT1 but not MUT KCNQ1OT1 (Fig. 5e, f). Ago2 is the essential component of the RNA-induced silencing complex (RISC)29. To determine whether KCNQ1OT1 binds miR-34c-5p in an Ago2-dependent manner, we performed anti-Ago2 RIP in U-2OS and 143B cells transiently overexpressing miR-34c-5p. Endogenous KCNQ1OT1 enrichment was increased after overexpression of miR-34c-5p in OS cells (Fig. 5h, i). Taken together, these results indicated that KCNQ1OT1 sponges miR-34c-5p and may function as a ceRNA in OS.
MiR-34c-5p inhibition reversed the inhibitory effect of OS cells induced by KCNQ1OT1 depletion
To explore whether KCNQ1OT1 exerted its function in OS cells through miR-34c-5p, we performed a rescue experiment by transfecting sh-KCNQ1OT1 plus miR-34c-5p inhibitors into U-2OS and 143B cells. The knockdown efficiency of miR-34c-5p inhibition was evaluated by RT-qPCR (Supplementary Fig. 5a). We found that downregulation of KCNQ1OT1 significantly inhibited protein expression of ALDOA, while the inhibition of miR-34c-5p partially rescued ALDOA expression in U-2OS and 143B cells (Fig. 6a). As shown in Fig. 6b–d, silence of miR-34c-5p reduced the inhibitory effect of KCNQ1OT1 knockdown on the growth of OS cells. Similarly, miR-34c-5p inhibition also partly restored the Warburg effect in U-2OS and 143B cells (Fig. 6e, f and Supplementary Fig. 5b, c). In an in vivo assay, a compromised tumorigenic potential in the KCNQ1OT1-knockdown group was partly offset via the silence of miR-34c-5p (Fig. 6g, h). Finally, the expression pattern of KCNQ1OT1/miR-34c-5p/ALDOA axis in human OS tissues and xenograft tumors were validated through fluorescence in situ hybridization (FISH) and immunofluorescence (IF) staining. A positive correlation between the expression pattern of KCNQ1OT1 and ALDOA, and a negative correlation between KCNQ1OT1 and miR-34c-5p, as well as miR-34c-5p and ALDOA were apparent (Supplementary Fig. 5d–g). Similarly, knockdown of KCNQ1OT1 also promoted the expression of miR-34c-5p and inhibited the expression of ALDOA in tumor tissues from a subcutaneous xenograft mouse model (Supplementary Fig. 5h). These results validated that KCNQ1OT1 promotes OS growth and the Warburg effect via serving as a ceRNA to sponge miR-34c-5p.
Accumulating evidence reports that dysregulated lncRNA is related to OS patient outcomes and affected the cancer progress. Yu et al.30 found that lncRNA taurine upregulated gene 1 (TUG1) promotes OS cell metastasis by mediating the miR-143-5p/HIF-1α pathway. Wang et al.31 revealed that lncRNA small nucleolar RNA host gene 16 (SNHG16) was highly expressed in OS and contributed to the growth of OS by promoting BCL9 expression via sponging miR-1301. Zhang et al.32 demonstrated that elevated long intergenic non-coding RNA 161 (LINC00161) reversed the cisplatin-resistant phenotype of OS cells by upregulating interferon-induced protein with tetratricopeptide repeats 2 (IFIT2). In this study, we discovered upregulated lncRNA KCNQ1OT1 in OS cell lines and tissues. In addition, KCNQ1OT1 promoted OS growth in vivo and also repressed apoptosis and stimulated cell proliferation in vitro. However, KCNQ1OT1 knockdown had little effect on the growth of the normal human osteoblast cell line hFOB1.19 (Supplementary Fig. 6a–c). Our findings revealed that KCNQ1OT1 was oncogenic and played a specific role in the occurrence and progression of OS.
LncRNA KCNQ1OT1 has been reported to be involved in cancer cell chemoresistance, growth, and invasion in a cell-type dependent manner33. In cholangiocarcinoma (CCA), KCNQ1OT1 was highly expressed and acted as a ceRNA to improve CCA proliferation and invasion by regulating the miR-140-5p/SOX4 axis34. Previous work demonstrated that KCNQ1OT1 inhibited the chemosensitivity to cisplatin (CDDP) through upregulation of KCNQ1OT1 via DNA methyltransferase (DNMT) in OS cell line MG-6335. In our study, we also showed that treatment of CDDP or sh-KCNQ1OT1 facilitated apoptosis of 143B and U-2OS cells, and the combination of CDDP and sh-KCNQ1OT1 enhanced this function (Supplementary Fig. 6d, e). More importantly, we elucidated the role of the KCNQ1OT1 in metabolic alterations in OS cells. We reported that silencing KCNQ1OT1 significantly decreased aerobic glycolysis and increased mitochondrial respiration in OS cells.
Increased aerobic glycolysis (the Warburg effect) facilitates cancer cell growth and survival, especially by providing more intermediates for many biosynthetic pathways and adapting to a hypoxic condition36,37,38,39. Therefore, targeting glycolysis has been demonstrated to be an effective method for controlling tumor growth and enhancing anticancer therapies. However, little is known about the role of lncRNA in glucose metabolism reprogramming in cancer cells. In this study, we report that KCNQ1OT1 is a novel promoter of the Warburg effect in OS by sponging miR-34c-5p, which directly targets the 3ʹUTR of ALDOA, a critical glycolytic enzyme.
ALDOA catalyzes the reversible conversion of fructose-1,6-bisphosphate to glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP)40. It is widely accepted that ALDOA is highly expressed and is correlated with poor survival outcomes in many kinds of harmful cancers10,11,12,13. We also found that ALDOA is upregulated in OS cells and tissues and related with worse overall survival rates. Our findings indicated that ALDOA contributed to the Warburg effect and enhanced growth of OS cells but not hFOB1.19 cells (Supplementary Fig. 6f–j).
In conclusion, our study identified KCNQ1OT1 as an oncogene that was highly expressed in OS. We suggest an important role for KCNQ1OT1 in glucose metabolism reprogramming via competitively binding miR-34c-5p to facilitate ALDOA expression in OS. These findings imply that KCNQ1OT1 may be a potential clinical therapeutic target for patients with OS.
Materials and methods
Two human osteosarcoma cell lines (MG63 and Saos-2) and human osteoblast hFOB1.19 cells were provided by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The human osteosarcoma U-2OS and 143B cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Mycoplasma contamination testing was performed using Mycoplasma genus-specific PCR. Each cell line passed the DNA profiling (STR) test. All of the cell lines were cultured on the basis of ATCC protocols. MG63, Saos-2, U-2OS, and 143B were incubated in a 5% CO2 atmosphere at 37 °C. Moreover, the hFOB1.19 cells were cultured in a 5% CO2 atmosphere at 34.5 °C.
Quantitative RT-PCR (qRT-PCR)
Total RNA from the cells was extracted and reverse transcribed as described before41. Real-time PCR analyses for miRNA or mRNA were performed on a 7500 Real-time PCR system (Applied biosystems) as previously described42. β-actin and U6 served as internal controls. All primers were listed in Supplementary Table 1.
The sequences of shRNAs targeting KCNQ1OT1 were sh-1, 5′-GCCAATAGCAACTGACTAA-3′ and sh-2, 5′-GCCACATCTAACACCTATA-3′. The plasmids, which contained the shRNA and the negative control were obtained from Gene Pharma (ShangHai, China). The negative control plasmid and the plasmid containing ALDOA-HA were purchased from OBiO Technology (Shanghai, China). We packaged these plasmids into virus particles using HEK 293 T cells and determined the viral titers. In order to establish stable KCNQ1OT1-knockdown cell lines or the ALDOA-overexpressing cell lines, the target cells were co-infected with 1 × 108 lentivirus-transducing and polybrene (Sigma, MO, USA). Furthermore, 2.5 μg/mL puromycin or 10 mg/mL blasticidin were used to screen the infected cells after 72 h. The efficiency of the knockdown or overexpression was verified by western blot or qRT-PCR.
Control mimics, miR-34a-5p mimics, miR-34c-5p mimics, miR-449a mimics, miR-449b-5p mimics, miR-877-3p mimics, control inhibitor, and miR-34c-5p inhibitor were obtained from Gene-Pharma (Shanghai, China). The targeted miRNA mimic, miRNA inhibitor, and miR-control were transfected into U-2OS and 143B cells at a concentration of 50 nM by using Lipofectamine 3000 (Invitrogen). hFOB1.19 cells were cultured at 60% confluence and transfected with ALDOA-specific small interfering (si) RNA or a negative control siRNA (GenePharma, Shanghai, China) using Lipofectamine® RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA). The efficiency of the knockdown or overexpression was verified by qRT-PCR or western blot.
Protein extraction and western blotting
Total proteins from the cells were extracted by using RIPA buffer (Thermo Fisher Scientific, Rockford, lL, USA) containing protease inhibitors (Roche, Mannheim, Germany). The western blotting assay was performed as previously described43. In general, all of the cellular proteins were extracted and 15–20 μg of proteins were separated by 5–10% SDS-PAGE gels. Following transfer of the proteins onto a membrane, the membranes were incubated overnight at 4 °C with the primary antibodies, including the antibodies to ALDOA (ab169544; Abcam, Cambridge, UK), α-Tubulin (#2125; Cell Signaling Technology, MA, USA), cleaved Caspase-3 (ab2302; Abcam, Cambridge, UK), cleaved Caspase-7 (#8438; Cell Signaling Technology, MA, USA), cleaved Caspase-9 (#9509; Cell Signaling Technology, MA, USA), CDK4 (#12790, Cell Signaling Technology, MA, USA) and Cyclin D1 (ab226977; Abcam, Cambridge, UK). The next day, the membranes were incubated with secondary antibodies after being washed. Finally, the membranes were detected using an ECL substrate (Share-bio, Shanghai, China).
The IHC assay was conducted with methods as previously described43. Ki67 was detected using the corresponding primary antibodies ki67 (GB13030; Servicebio, Wuhan, China) at 1:200 dilutions.
Cell proliferation assays and cell apoptosis assay
Cell proliferation assays, including CCK-8 assay, colony formation assay, and cell apoptosis assay, were performed as previously described43. Three independent experiments were performed.
EdU incorporation assay
The EdU incorporation assay was performed using a BeyoClick™ EdU Cell Proliferation Kit (C0075S, Beyotime Biotechnology, Shanghai, China) according to the instructions. Briefly, target OS cells were planted in the 12-well chambers (Ibidi, Germany), and 200 μl EdU (50 μM) was added to each well and incubated for 2 h. Thereafter, the cell was fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.3% Triton X-100 for 10 min at room temperature. Next, the cells were washed again and labeled with 5 μg/ml of Hoechst 33342 for 30 min. Confocal microscopy (LSM 510, META laser scanning microscope, Zeiss) was used to acquire the images. Three independent experiments were performed.
Cell cycle analysis
Cell cycle assay was performed using a Cell Cycle Analysis Kit (MultiSciences Biotech Co, Hangzhou, China) as previously described43. Three independent experiments were performed.
Mouse xenograft assay
This experiment was performed with 6-week-old male BALB/C nude mice. Mice were manipulated and housed as previously described41. All animal studies were approved by the Research Ethics Committee of East China Normal University. Firstly, the mice were randomly divided into several groups and subcutaneously injected with 1.5 × 106 of the target cells (n = 5 per group). Volume of the xenografted tumor was measured every 5 days and was calculated with the following formula: volume (mm3) = (length × width2)/2. On day 20, all mice were euthanized, and the tumors were collected and measured. Tissue samples were then fixed for further immunohistochemistry assay analysis.
TUNEL assay was performed to quantify the proportion of apoptotic cells in the xenograft tumors as previously described by using a TUNEL kit (Roche, Basel, Switzerland)43.
Measurement of cellular glycolysis and oxidative phosphorylation
Glycolysis was measured as the rate of extracellular acidification (ECAR), and oxidative phosphorylation was measured as the OCR via use of the XF96 metabolic flux analyzer (Seahorse Biosciences, Billerica, MA, USA) as previously described43. Three independent experiments were performed.
Measurement of cellular ATP level and lactate production
An ATP assay kit (Promega, Madison, WI) was used to measure the cellular ATP level according to the manufacturer’s instructions. Bioluminescence was determined on a fluorescence luminometer (PerkinElmer, Waltham, MA). The ATP level was calculated from a standard curve. A lactate assay kit (BioVision, USA) was used to detect extracellular lactate levels according to the manufacturer’s protocol. All values were normalized to the cellular protein level. Three independent experiments were performed.
Dual-luciferase reporter assay
The ALDOA 3ʹUTR sequence containing the predicted binding site of miR-34c-5p in ALDOA and the mutant sequence or the KCNQ1OT1 3ʹUTR sequence containing the predicted binding site of miR-34c-5p in KCNQ1OT1 and the mutant sequence were synthesized and sub-cloned into the pmirGLO Vector. U-2OS and 143B cells were co-transfected with the luciferase reporters, along with miR-34c-5p mimic, or the negative control using Lipofectamine 2000 (Invitrogen). Following 48 h, the relative luciferase activity was measured with the dual-luciferase reporter assay system (Promega, Madison, USA). Three independent experiments were performed.
RIP was performed using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, MA, USA) according to the manufacturer’s protocol. In brief, 1 × 107 U-2OS and 143B cells transfected with pMS2bp-GFP and MS2, MS2-KCNQ1OT1, or miR-34c-5p mimic, and NC mimic were lysed in the RIP lysis buffer containing a protease inhibitor cocktail. Next, the cell supernatant was incubated with the RIP buffer containing a magnetic bead conjugated with antibodies against GFP (ab290, Abcam, UK), human AGO 2 (C34C6, CST, MA, USA) or the control normal mouse IgG (AP101, Millipore). Then the DNA and protein in the RIP complex were removed by using RNase-free DNase I and Proteinase K consecutively. Subsequently, the gained immunoprecipitated RNA was isolated and subjected to qRT-PCR to detect the enrichment of GFP, ALDOA, miR-34c-5p, or KCNQ1OT1. Three independent experiments were performed.
RNA pull-down assay
The commercially synthesized biotin-labeled KCNQ1OT1 was purchased from Genepharma (Shanghai, China) and transfected into U-2OS and 143B cells for 48 h. Then, the cell lysate was incubated with Dynabeads M‐280 Streptavidin (Sigma, MO, USA) according to the manufacturer’s instructions. TRIzol was used to elute and purify the interacted RNA complex, and qRT-PCR was used to measure the expression level of miR-34c-5p. Three independent experiments were performed.
A microarray containing tissue from 40 OS patients was obtained from Alena Biotechnology Co., Ltd. (Xi’an, China). Immunofluorescence was performed as previously described41. Antibodies to ALDOA (CY7206; Abways, Shanghai, China) were used in IF. Confocal microscopy (LSM 510, META laser scanning microscope, Zeiss) was used to acquire the images. The intensities of ALDOA staining were scored using the following staining criteria 0–5% was scored as 0; 6–35% was scored as 1; 36–70% was scored as 2; and >70% was scored as 3. A total score <2 was considered to represent the negative expression, and a score ≥2 was defined as a positive expression. The scoring was performed blind and determined by two senior pathologists.
Fluorescence in situ hybridization (FISH)
A microarray containing tissue from 40 OS patients was obtained from Alena Biotechnology Co., Ltd. (Xi’an, China). OS tissue sections were hybridized with the lncRNA KCNQ1OT1 (BioTNT Biotechnologies, Shanghai, China) and miR-34c-5p probes (Servicebio, Wuhan, China). Probe mix was denatured at 85 °C and hybridization was conducted at 65 °C overnight. Sections were washed using reducing concentrations of saline sodium citrate. Then slides were treated with 5% blocking solution for 30 min at room temperature. Each section was incubated with 100 μl HRP-labeled anti-DIG antibody at 1:500 in blocking buffer overnight at 4 °C. Then washed with TBS and TSA staining solution was created with a Perkin-Elmer TSA Plus kit according to the manufacturer’s instructions. Incubated in DAPI-containing TBS, then rinsed in water, air dried, and mounted in an aqueous fluorescence mounting media. Confocal microscopy (LSM 510, META laser scanning microscope, Zeiss) was used to acquire the images. The intensities of KCNQ1OT1 and miR-34c-5p staining were scored using the following staining criteria: 0–5% was scored as 0; 6–35% was scored as 1; 36–70% was scored as 2; and >70% was scored as 3. A total score <2 was considered to represent negative expression, and a score ≥2 was defined as a positive expression. The scoring was performed blind and determined by two senior pathologists.
The data from the R2 database was used to analyze the relationship between ALDOA expression and the overall survival of the OS patient (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). The data from TargetScan (http://www.targetscan.org/), miRDB (http://www.mirdb.org/), and StarBase (http://starbase.sysu.edu.cn/index.php) were used to analyze potential interaction genes of miR-34c-5p or KCNQ1OT1.
All statistics were performed using GraphPad Prism 7.0 and SPSS 16.0 software. Two-tailed Student’s t-test was used to calculate the statistical significance between groups. The chi-square test (SPSS 17.0; IBM, Armonk, NY, USA) was used to evaluate the correlation between the expression of KCNQ1OT1, miR-34c-5p, and ALDOA in human OS tissues. All data from the experiments were expressed as the mean ± standard deviation (SD). The statistical results obtained from the independent and randomized experiment, three replicates, and the p-value < 0.05 was considered statistically significant (p values > 0.05 = ns, p values < 0.05 = *, p values < 0.01 = **, p values < 0.001 = ***).
Zheng, W. et al. Nomogram application to predict overall and cancer-specific survival in osteosarcoma. Cancer Manag. Res. 10, 5439–5450 (2018).
Kovac, M. et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat. Commun. 6, 8940 (2015).
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA A Cancer J. Clin. 63, 11–30 (2013).
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11–20 (2008).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703–707 (2008).
Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
Chang, Y. C. et al. Feedback regulation of ALDOA activates the HIF-1alpha/MMP9 axis to promote lung cancer progression. Cancer Lett. 403, 28–36 (2017).
Lessa, R. C. et al. Identification of upregulated genes in oral squamous cell carcinomas. Head. Neck 35, 1475–1481 (2013).
Peng, Y. et al. New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer. Mol. Biosyst. 8, 3077–3088 (2012).
Oparina, N. Y. et al. [Differential expression of genes that encode glycolysis enzymes in kidney and lung cancer in humans]. Genetika 49, 814–823 (2013).
Hamaguchi, T. et al. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int. J. Oncol. 33, 725–731 (2008).
Chen, X. et al. Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma. Mol. Carcinogenesis 53, 138–144 (2014).
Long, F., Cai, X., Luo, W., Chen, L. & Li, K. Role of aldolase A in osteosarcoma progression and metastasis: in vitro and in vivo evidence. Oncol. Rep. 32, 2031–203 (2014).
Derrien, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 22, 1775–1789 (2012).
Bonasio, R. & Shiekhattar, R. Regulation of transcription by long noncoding RNAs. Annu. Rev. Genet. 48, 433–455 (2014).
Wilusz, J. E., Freier, S. M. & Spector, D. L. 3’ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 135, 919–932 (2008).
Kartha, R. V. & Subramanian, S. Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation. Front. Genet. 5, 8 (2014).
Tay, Y., Rinn, J. & Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344–352 (2014).
Peng, W. X., Koirala, P. & Mo, Y. Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 36, 5661–5667 (2017).
Wang, S. H. et al. Upregulation of H19 indicates a poor prognosis in gallbladder carcinoma and promotes epithelial-mesenchymal transition. Am. J. Cancer Res. 6, 15–26 (2016).
Shi, X. et al. Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer. EBioMedicine 37, 177–187 (2018).
Dong, Z. et al. KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis. J. Cell. Physiol. 234, 11304–11314 (2019).
Zhang, S. et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 9, 742 (2018).
Feng, W. et al. The dysregulated expression of KCNQ1OT1 and its interaction with downstream factors miR-145/CCNE2 in breast cancer cells. Cell. Physiol. Biochem. 49, 432–446 (2018).
Bian, Y. et al. KCNQ1OT1/miR-217/ZEB1 feedback loop facilitates cell migration and epithelial-mesenchymal transition in colorectal cancer. Cancer Biol. Ther. 20, 886–896 (2019).
Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325–337 (2011).
Bose, M., Barman, B., Goswami, A. & Bhattacharyya, S. N. Spatiotemporal uncoupling of microRNA-mediated translational repression and target RNA degradation controls microRNP recycling in mammalian cells. Mol. Cell. Biol. 37, e00464 (2017).
Yu, X. et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1alpha via miR-143-5p. Cell Death Dis. 10, 280 (2019).
Wang, X., Hu, K., Chao, Y. & Wang, L. LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis. Biomed. Pharmacother. 114, 108798 (2019).
Wang, Y. et al. Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. Cancer Lett. 382, 137–146 (2016).
Chiesa, N. et al. The KCNQ1OT1 imprinting control region and non-coding RNA: new properties derived from the study of Beckwith-Wiedemann syndrome and Silver-Russell syndrome cases. Hum. Mol. Genet. 21, 10–25 (2012).
Sun, H., Li, Y., Kong, H., Dai, S. & Qian, H. Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis. Arch. Biochem. Biophys. 658, 7–15 (2018).
Qi, X. et al. Knockdown of KCNQ1OT1 suppresses cell invasion and sensitizes osteosarcoma cells to CDDP by upregulating DNMT1-mediated Kcnq1 expression. Mol. Ther. Nucleic Acids 17, 804–818 (2019).
Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464 (2011).
Lu, J., Tan, M. & Cai, Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 356, 156–164 (2015).
Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 749 (2016).
Chen, F. et al. Extracellular vesicle-packaged HIF-1alpha-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 21, 498–510 (2019).
Tochio, T., Tanaka, H., Nakata, S. & Hosoya, H. Fructose-1,6-bisphosphate aldolase A is involved in HaCaT cell migration by inducing lamellipodia formation. J. Dermatol. Sci. 58, 123–129 (2010).
Shen, Y. et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine 40, 210–223 (2019).
Weng, Y. et al. The miR-15b-5p/PDK4 axis regulates osteosarcoma proliferation through modulation of the Warburg effect. Biochem. Biophys. Res. Commun. 503, 2749–2757 (2018).
Zhao, S. J. et al. SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway. Cell Death Dis. 9, 390 (2018).
We are thankful to Dr. Yuqing Jiang, Dr. Haibo Li (Department of Orthopedics, Changzhou No. 2 People’s Hospital, Nanjing Medical University, Changzhou, Jivangsu 213003, China), and Dr. Juntan (Department of Orthopedics, Shanghai East Hospital, School of Medicine, Shanghai Tongji University) for assistance with our studies. This work was supported by Changzhou Sci&Tech Program (No. CJ20190083).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by M. Agostini
About this article
Cite this article
Shen, Y., Xu, J., Pan, X. et al. LncRNA KCNQ1OT1 sponges miR-34c-5p to promote osteosarcoma growth via ALDOA enhanced aerobic glycolysis. Cell Death Dis 11, 278 (2020). https://doi.org/10.1038/s41419-020-2485-1